Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study

Michael Lott, John H. Greist, James W. Jefferson, Kenneth A. Kobak, David J. Katzelnick, Richard J. Katz, Sarah C. Schaettle

Research output: Contribution to journalArticle

83 Scopus citations

Abstract

The safety and efficacy of brofaromine, a reversible and selective monoamine oxidase inhibitor, were examined in a multicenter trial of 102 outpatients with social phobia. After a 1-week placebo washout, subjects were randomly assigned to 10 weeks of treatment with either brofaromine (N = 52) or placebo (N = 50). Brofaromine dosage began at 50 mg/day and was titrated to a maximum of 150 mg/day, depending on treatment response. Brofaromine produced a significantly greater change from baseline in Liebowitz Social Anxiety Scale (LSAS) scores compared with placebo, F(1) = 6.01, p < 0.016. Mean LSAS scores decreased from 81.8 at baseline to 62.6 at endpoint for brofaromine, t = 5.41, p < 0.001, and from 79.8 to 70.7 for placebo, t = 3.66, p < 0.001. Eleven of the 14 brofaromine early terminators discontinued because of adverse experiences, as did 4 of the 17 placebo early terminators. Side effects more common with brofaromine than placebo included insomnia, dizziness, dry mouth, anorexia, tinnitus, and tremor. No clinically significant variations in vital signs or laboratory values were found. The findings are consistent with the clinical efficacy for the treatment; of social phobia.

Original languageEnglish (US)
Pages (from-to)255-260
Number of pages6
JournalJournal of Clinical Psychopharmacology
Volume17
Issue number4
DOIs
StatePublished - Aug 1 1997

    Fingerprint

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this